Alto Neuroscience (ANRO) Common Equity (2023 - 2026)
Alto Neuroscience (ANRO) posted Common Equity of $3000.0 for Q1 2026, down 100.0% sequentially from $151.1 million in Q4 2025, and down 100.0% YoY from $139.1 million in Q1 2025.
Alto Neuroscience (ANRO) Common Equity (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Common Equity for 4 years, with the latest figure at $3000.0 in Q1 2026.
- Quarterly Common Equity fell 100.0% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3000.0 (down 100.0% YoY) and the FY2025 annual result came in at $151.1 million, changed 0.21% from the prior year.
- Common Equity eased to $3000.0 in Q1 2026 per ANRO's latest filing, from $151.1 million in the prior quarter.
- Over five years, Common Equity peaked at $193.1 million in Q1 2024 and troughed at -$71.7 million in Q4 2023.
- A 4-year average of $67.1 million and a median of $123.4 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity soared 526.99% in 2024, then sank 100.0% in 2025.
- Over 4 years, Common Equity stood at -$71.7 million in 2023, then surged by 311.32% to $151.5 million in 2024, then declined by 0.21% to $151.1 million in 2025, then sank by 100.0% to $3000.0 in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $3000.0, $151.1 million, and $3000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 219.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 219.25 Mn |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 151.14 Mn |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 123.41 Mn |
| Mar 31, 2025 | 139.10 Mn |
| Dec 31, 2024 | 151.46 Mn |
| Sep 30, 2024 | 165.05 Mn |
| Jun 30, 2024 | 179.78 Mn |
| Mar 31, 2024 | 193.10 Mn |
| Dec 31, 2023 | -71.67 Mn |
| Sep 30, 2023 | -61.10 Mn |
| Jun 30, 2023 | -52.60 Mn |
| Mar 31, 2023 | -45.23 Mn |